Ventyx Biosciences: Cautious Optimism Amidst Sanofi’s Strategic Investment and Upcoming Clinical Trials
H.C. Wainwright analyst Emily Bodnar maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target ...
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for ...
Ventyx stock climbs 8% on $27M Sanofi investment
Ventyx (VTYX) stock jumped 8% on news that Sanofi (SNY) has made a $27M strategic investment in the company at an ...
Business Insider16h
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a ...